< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

HGF webinar: Getting your first filing right

März 2022

Veranstaltungsdatum: 23. März 2022

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right.

One of the most often asked questions of patent attorneys is: “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is especially so in the therapeutic field where wide breadth of claim is desired coupled with maximum use of the available 21 year patent term from first filing. Circumstances can nevertheless necessitate a first filing needing to be considered in a pressurised situation. Even so, strategy from the start needs to be a matter of careful consideration to avoid later problems. The CRISPR patent battle in Europe illustrates well how first filing issues can be a source of costly, unwanted problems which are avoidable.

This presentation covered the considerations required at the first filing stage to align patenting strategy with commercial strategy and minimise problems arising from both formal and content issues. The presentation covered such issues as the evidence required to get over the plausibility hurdle in relation to inventive step and sufficiency as applied to compound and therapeutic use claims, as well as formal considerations such as where to file and who should file, often especially important considerations in the case of collaborative projects involving inventors outside the UK. The presentation also dealt with how to ensure you keep priority of a first filing both legally and to maximise disclosure benefit.

Speaker

Dr Claire Irvine – Partner & Patent Attorney

Watch the webinar:

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen